secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001493152-23-017398
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q1 revenue $15.5M, up 99% YoY; net loss narrows to $1.2M
-----------------------------------------------------------------------

- Net revenues $15.5M (99% YoY increase); net loss $1.2M vs $3.2M prior year.
- Gross margin 86% vs 90% prior year due to lower margins on Scendia products.
- SG&A $13.0M (up $3.6M) driven by higher sales commissions and sales force expansion.
- Scendia sales flat at $3.0M; ALLOCYTE supply issues persist, expected resolution H2 2023.
- Received 510(k) clearance for BIASURGE Advanced Surgical Solution; preparing launch late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315223017398/0001493152-23-017398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315223017398/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-017398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer